Indications and effects of Rucaparib targeted drug

Rucaparib (Rucaparib) is a PARP inhibitor that mainly inhibits the repair function of polyadenosine diphosphate ribose polymerase (PARP) enzyme, preventing DNA damage in tumor cells from being effectively repaired, and ultimately inducing cancer cell apoptosis. This mechanism is particularly significant in patients carrying BRCA1 or BRCA2 gene mutations, because the DNA repair pathways of these patients are inherently defective. Further blocking the repair function of PARP can significantly improve the therapeutic effect. From the perspective of molecular targeting, rucapanib is one of the important achievements of precision medicine, especially in the treatment of gynecological tumors and some prostate cancers, showing outstanding application prospects.

In terms of indications, data show that rucapanib was initially approved for ovarian cancer patients who have received multiple lines of chemotherapy, especially those with recurrent ovarian cancer with BRCA mutations. Subsequently, as more research progressed, its application scope gradually expanded, not only limited to ovarian cancer, but also including fallopian tube cancer, primary peritoneal cancer, prostate cancer and other related diseases. In recent years, some clinical explorations have also been carried out in prostate cancer and pancreatic cancer populations. Especially in patients with hereditary DNA repair gene mutations, rucapanib has shown certain anti-tumor activity. This also allows it to gradually occupy a place in the development of precision oncology.

The role of rucapanib is not only reflected in tumor control, but also has potential value in delaying disease progression and prolonging progression-free survival. For patients, the emergence of PARP inhibitors has changed the traditional single treatment model that relies on chemotherapy, allowing more patients to achieve long-term management through oral small molecule targeted drugs. As an oral formulation, the convenience of rucapanib supports patient treatment compliance and enables outpatient management.

Reference materials:https://www.drugs.com/mtm/rucaparib.html